Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Benchmarks for the Assessment of Novel Cardiovascular Biomarkers

Benchmarks for the Assessment of Novel Cardiovascular Biomarkers Editorial Benchmarks for the Assessment of Novel Cardiovascular Biomarkers David A. Morrow, MD, MPH; James A. de Lemos, MD he investigation of novel circulating serum and able cost. Evaluation of these properties requires that each plasma biomarkers in patients with cardiovascular new biomarker and its assay(s) undergo a thorough exami- Tdisease has been accelerating at a remarkable pace. nation of preanalytical (eg, conditions of measurement, sam- For example, a Medline search that uses the terms “biomar- ple handling, sample type), and analytical performance. kers” and “acute coronary syndromes” (ACS) reveals an Although it would seem necessary for these steps to be approximate tripling in the number of published reports completed early in the development of a biomarker, they are during the 2-year interval from 2003 to 2004 compared with often undertaken after initial epidemiological studies bring the period from 2001 to 2002, and this number more than attention to the new biochemical test. For example, after doubled from 2005 to 2006. Although this expanding body of promising experimental and epidemiological data established research has established firm evidence for the value of links between soluble CD40 ligand and atherothrombosis, biomarkers, such as for diagnosis and risk assessment among further investigation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

Benchmarks for the Assessment of Novel Cardiovascular Biomarkers

de Lemos, James A.
Circulation , Volume 115 (8) – Feb 1, 2007
Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/benchmarks-for-the-assessment-of-novel-cardiovascular-biomarkers-C8Ts5USiC3

References (16)

ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.106.683110
pmid
17325253
Publisher site
See Article on Publisher Site

Abstract

Editorial Benchmarks for the Assessment of Novel Cardiovascular Biomarkers David A. Morrow, MD, MPH; James A. de Lemos, MD he investigation of novel circulating serum and able cost. Evaluation of these properties requires that each plasma biomarkers in patients with cardiovascular new biomarker and its assay(s) undergo a thorough exami- Tdisease has been accelerating at a remarkable pace. nation of preanalytical (eg, conditions of measurement, sam- For example, a Medline search that uses the terms “biomar- ple handling, sample type), and analytical performance. kers” and “acute coronary syndromes” (ACS) reveals an Although it would seem necessary for these steps to be approximate tripling in the number of published reports completed early in the development of a biomarker, they are during the 2-year interval from 2003 to 2004 compared with often undertaken after initial epidemiological studies bring the period from 2001 to 2002, and this number more than attention to the new biochemical test. For example, after doubled from 2005 to 2006. Although this expanding body of promising experimental and epidemiological data established research has established firm evidence for the value of links between soluble CD40 ligand and atherothrombosis, biomarkers, such as for diagnosis and risk assessment among further investigation

Journal

Circulation – Wolters Kluwer Health

Published: Feb 1, 2007

There are no references for this article.